

Eduardo Ramacciotti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5140968/eduardo-ramacciotti-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78
papers

1,532
citations

20
h-index

38
g-index

86
ext. papers

2,003
ext. citations

5.3
avg, IF

4.39
L-index

#	Paper	IF	Citations
78	Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial.. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022 , 28, 10760296211073922	3.3	
77	Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.. <i>Lancet, The</i> , 2021 ,	4.0	34
76	USP Standardized Mixtures of Bovine, Ovine and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single Sourced Heparins and May be Interchangeable,. <i>Blood</i> , 2021 , 138, 1067-1067 ²²		
75	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 992-1007	7	6
74	Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. <i>Lancet, The</i> , 2021 , 397, 2253-2263	4.0	150
73	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021 , 27, 10760296211021498	3.3	25
72	Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulation cOroNavius)-Coalition IV trial. <i>American Heart Journal</i> , 2021 , 238, 1-11	4.9	10
71	Medically Ill hospitalized Patients for COVID-19 THrombosis Extended Prophylaxis with rivaroxaban Therapy: Rationale and Design of the MICHELLE Trial. <i>American Heart Journal</i> , 2021 , 242, 115-122	4.9	10
70	Guidance on diagnosis, prevention and treatment of thromboembolic complications in COVID-19: a position paper of the Brazilian Society of Thrombosis and Hemostasis and the Thrombosis and Hemostasis Committee of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapies. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 222-230	1.6	15
69	Rationale and design for the study Apixaban versus Clopidogrel on a background of aspirin in patient undergoing InfraPopliteal angioplasty for critical limb ischemia: AGRIPPA trial. <i>American Heart Journal</i> , 2020 , 227, 100-106	4.9	10
68	Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 1076029620936330	3.3	19
67	Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 1076029619851204	3.3	14
66	Assay Dependent Reversal of the Oral and Parenteral Anti-Xa Agents By Andexanet Alfa. <i>Blood</i> , 2020 , 136, 39-40	2.2	
65	Heparinox, a generic version of low molecular weight heparin enoxaparin, is bioequivalent to the branded version. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
64	Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 1076029620960820	3.3	0
63	Drug-Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 1076029620936325	3.3	4
62	Porcine Mucosal Heparin Shortage Crisis! What Are the Options?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029619878786	3.3	14

61	Zika and Chikungunya Virus and Risk for Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029618821184	3-3	34
60	Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029619856433	3-3	2
59	Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil: The BRIDGE Cardiovascular Prevention Cluster Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019 , 4, 408-417	16.2	14
58	Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029619863493	3-3	8
57	Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition. <i>Thrombosis Research</i> , 2019 , 184, 44-49	8.2	6
56	A Factor Xa Inhibitor Antidote (andexanet alfa) is Capable of Neutralizing the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin in a Comparable Manner as Protamine Sulfate. <i>FASEB Journal</i> , 2019 , 33, lb37	0.9	
55	Reversal of the Thrombin Generation Inhibitory Effect of Apixaban, Betrixaban, Edoxaban and Rivaroxaban by Andexanet Alpha may be Associated with Increased Thrombogenesis. <i>FASEB Journal</i> , 2019 , 33, 515.1	0.9	
54	Potency Adjusted Bovine Heparin is Comparable to Porcine Heparin in Patients Undergoing Open Heart Surgery. <i>FASEB Journal</i> , 2019 , 33, 819.8	0.9	
53	Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint. <i>International Angiology</i> , 2018 , 37, 255-260	2.2	1
52	Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018 , 24, 1208-1215	3-3	3
51	Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018 , 24, 340S-349S	3-3	2
50	Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017 , 37, 942-948	9-4	19
49	Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017 , 23, 883-887	3-3	22
48	Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1518-1527	7	6
47	Betrixaban for VTE Prevention in the Medically Ill Population, the APEX Trial: Good News for This Needy Population?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017 , 23, 701-702	3-3	2
46	Warfarin Discontinuation in Patients With Unprovoked Venous Thromboembolism: A Large US Insurance Database Analysis. <i>American Journal of Therapeutics</i> , 2016 , 23, e1744-e1753	1	2
45	Rediscovering Anticoagulation in Distal Deep Venous Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016 , 22, 772-778	3-3	9
44	Enoxaparin Treatment Followed by Rivaroxaban for the Treatment of Acute Lower Limb Venous Thromboembolism: Initial Experience in a Single Center. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016 , 22, 377-80	3-3	4

43	Idarucizumab, a Specific Antidote for Dabigatran, Cross-React with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds. <i>Blood</i> , 2016 , 128, 3836-3836	2.2	
42	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 809-16	7	13
41	Pharmacological Prophylaxis for Venous Thromboembolism Among Hospitalized Patients With Acute Medical Illness: An Electronic Medical Records Study. <i>American Journal of Therapeutics</i> , 2016 , 23, e328-35	1	3
40	A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism. <i>American Journal of the Medical Sciences</i> , 2016 , 352, 92-106	2.2	17
39	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016 , 375, 534-44	59.2	286
38	Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 245-52	15.4	89
37	Venous thromboembolism prophylaxis and clinical consequences in medically ill patients. <i>American Journal of Therapeutics</i> , 2013 , 20, 132-42	1	17
36	Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 444-51	15.4	23
35	Bleeding Incidence Among Patients With Venous Thromboembolism: A Large US Insurance Database Analysis. <i>Blood</i> , 2013 , 122, 2916-2916	2.2	1
34	Apixaban: an oral direct factor-xa inhibitor. <i>Advances in Therapy</i> , 2012 , 29, 187-201	4.1	12
33	Enoxaparin dosing after discharge from US hospitals in patients with total knee replacement. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012 , 18, 514-8	3.3	2
32	An open label, non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011 , 17, 66-9	3.3	8
31	Latero-lateral femoro-femoral arteriovenous fistula: a new surgical approach for hemodialysis patients with no vascular access. <i>Acta Cirurgica Brasileira</i> , 2011 , 26, 72-6	1.6	4
30	Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism. <i>Phlebology</i> , 2011 , 26, 3-7	2	3
29	Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011 , 17, 126-35	3.3	17
28	Evaluation of soluble P-selectin as a marker for the diagnosis of deep venous thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011 , 17, 425-31	3.3	63
27	Generic versus branded enoxaparin in the prevention of venous thromboembolism following major abdominal surgery: report of an exploratory clinical trial. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011 , 17, 633-9	3.3	12
26	Pharmacologic Prophylaxis for Venous Thromboembolism Among Hospitalized Patients with Acute Medical Illness: An Electronic Medical Records Study. <i>Blood</i> , 2011 , 118, 2074-2074	2.2	

25	Chemically oversulfated glycosaminoglycans are potent modulators of contact system activation and different cell signaling pathways. <i>Journal of Biological Chemistry</i> , 2010 , 285, 22966-75	5.4	48
24	Gender-dependent differential phosphorylation in the ERK signaling pathway is associated with increased MMP2 activity in rat aortic smooth muscle cells. <i>Journal of Surgical Research</i> , 2010 , 160, 18-24	2.5	30
23	P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis. <i>Thrombosis Research</i> , 2010 , 125, e138-42	8.2	36
22	Do galectins play a role in venous thrombosis? a review. <i>Thrombosis Research</i> , 2010 , 125, 373-6	8.2	20
21	Proteomics of microparticles after deep venous thrombosis. <i>Thrombosis Research</i> , 2010 , 125, e269-74	8.2	61
20	Pharmacodynamic differences between biosimilar and branded enoxaparins with reference to their immunogenic profile. <i>FASEB Journal</i> , 2010 , 24, lb490	0.9	2
19	Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 748-754	7	72
18	El inhibidor tisular de la metaloproteinasa-1 es un marcador temprano de disfunci3n endotelial en un modelo murino de lesi3n oxidativa venosa. <i>Annals of Vascular Surgery</i> , 2009 , 23, 551-559		
17	Vascular flow of the gastric fundus after arterial devascularization: an experimental study. <i>Journal of Surgical Research</i> , 2009 , 152, 128-34	2.5	7
16	Tissue inhibitor of metalloproteinase-1 is an early marker of acute endothelial dysfunction in a rodent model of venous oxidative injury. <i>Annals of Vascular Surgery</i> , 2009 , 23, 498-505	1.7	10
15	LInhibiteur tissulaire de la mtalloprotinase-1 est un marqueur pr3coce de dysfonction aigu3 endoth3liale dans un mod3le de l3sion veineuse oxydative chez le rongeur. <i>Annales De Chirurgie Vasculaire</i> , 2009 , 23, 538-546		
14	Microparticle surface protein are associated with experimental venous thrombosis: a preliminary study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009 , 15, 201-8	3.3	8
13	Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 748-54	7	31
12	Protease Generation by Chondroitin Sulfate, Semisynthetic OSCS Preparations and Contaminants Isolated From Heparin.. <i>Blood</i> , 2009 , 114, 3133-3133	2.2	
11	Oversulfated Chondroitin Sulfate Is Not the Sole Contaminant in Recalled Heparin Preparations.. <i>Blood</i> , 2009 , 114, 1070-1070	2.2	
10	Contaminants Isolated From Recalled Heparin Are Not All the Same: Clinical Implications.. <i>Blood</i> , 2009 , 114, 1069-1069	2.2	
9	Contaminated heparin preparations, severe adverse events and the contact system. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008 , 14, 489-91	3.3	6
8	A cost analysis of the treatment of patients with post-thrombotic syndrome in Brazil. <i>Thrombosis Research</i> , 2006 , 118, 699-704	8.2	20

7	Vein Imaging. <i>Dermatologic Surgery</i> , 2006 , 32, 1031-1038	1.7	8
6	Vein imaging: a new method of near infrared imaging, where a processed image is projected onto the skin for the enhancement of vein treatment. <i>Dermatologic Surgery</i> , 2006 , 32, 1031-8	1.7	61
5	An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. <i>Thrombosis Research</i> , 2004 , 114, 149-53	8.2	27
4	Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. <i>Thrombosis Research</i> , 2003 , 109, 171-4	8.2	45
3	Comparative blood flow study of arteriovenous fistulae in canine femoral arteries: modified latero-lateral and end-lateral techniques. <i>Artificial Organs</i> , 2000 , 24, 235-40	2.6	4
2	Endovascular de Fístulas Artfiovenosas. <i>Acta Cirurgica Brasileira</i> , 1999 , 14, 47-51	1.6	2
1	Distribuição anatômica da fístula ductal pancreática do cão: implicações para o isolamento das ilhotas de Langerhans. <i>Acta Cirurgica Brasileira</i> , 1999 , 14, 131-135	1.6	